TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
| ITEM 5. | OTHER INFORMATION |
|---|
Director and Officer Rule
10b5-1
Trading Arrangements
During the three months ended September 30, 2025, the following officer adopted a Rule
10b5-1
trading arrangement (as such term is defined in Item 408 of Regulation
S-K).
The trading plan is intended to satisfy the affirmative defense of Rule
10b5-1(c)
under the Exchange Act.
| Name and Title | Date | Expiration Date | Maximum SharesSubject to Plan (1) |
|---|---|---|---|
| Christine Fox, Executive Vice President, U.S. Commercial | August 11, 2025 | March 6, 2026 | 101,772 |
| (1) | The plan includes shares to be sold solely to cover tax withholding obligations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.